Next Article in Journal
Digital Phenotyping in Bipolar Disorder: Which Integration with Clinical Endophenotypes and Biomarkers?
Previous Article in Journal
Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450
Previous Article in Special Issue
Immune-Checkpoint Blockade Therapy in Lymphoma
Open AccessReview

Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia

Interactions with the Environment Program, Immune System Development and Function Unit, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, 28049 Madrid, Spain
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(20), 7685; https://doi.org/10.3390/ijms21207685
Received: 30 September 2020 / Revised: 13 October 2020 / Accepted: 14 October 2020 / Published: 16 October 2020
(This article belongs to the Special Issue Novel Approaches to Hematologic Malignancies by Immunotherapy)
T-cell acute lymphoblastic leukemia (T-ALL), a T-cell malignant disease that mainly affects children, is still a medical challenge, especially for refractory patients for whom therapeutic options are scarce. Recent advances in immunotherapy for B-cell malignancies based on increasingly efficacious monoclonal antibodies (mAbs) and chimeric antigen receptors (CARs) have been encouraging for non-responding or relapsing patients suffering from other aggressive cancers like T-ALL. However, secondary life-threatening T-cell immunodeficiency due to shared expression of targeted antigens by healthy and malignant T cells is a main drawback of mAb—or CAR-based immunotherapies for T-ALL and other T-cell malignancies. This review provides a comprehensive update on the different immunotherapeutic strategies that are being currently applied to T-ALL. We highlight recent progress on the identification of new potential targets showing promising preclinical results and discuss current challenges and opportunities for developing novel safe and efficacious immunotherapies for T-ALL. View Full-Text
Keywords: T-cell acute lymphoblastic leukemia; immunotherapy; monoclonal antibodies; chimeric antigen receptor; relapse; leukemia-initiating cells T-cell acute lymphoblastic leukemia; immunotherapy; monoclonal antibodies; chimeric antigen receptor; relapse; leukemia-initiating cells
Show Figures

Figure 1

MDPI and ACS Style

Bayón-Calderón, F.; Toribio, M.L.; González-García, S. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia. Int. J. Mol. Sci. 2020, 21, 7685.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop